These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 6160907

  • 1. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
    Miura T, Maekawa T, Kurashige S, Mitsuhashi S.
    Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
    [Abstract] [Full Text] [Related]

  • 2. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC, Prager MD.
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [Abstract] [Full Text] [Related]

  • 3. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
    Bowlin TL, Prakash NJ, Edwards ML, Sjoerdsma A.
    Cancer Res; 1991 Jan 01; 51(1):62-6. PubMed ID: 1988107
    [Abstract] [Full Text] [Related]

  • 4. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
    Kataoka T, Oh-hashi F.
    Cancer Res; 1985 Jul 01; 45(7):2962-6. PubMed ID: 3873988
    [Abstract] [Full Text] [Related]

  • 5. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
    Nagase F, Ueda K, Kawashima K, Jamshedur Rahman SM, Isobe K, Yoshida T, Hasegawa Y, Ando K, Iwamoto T, Nagura E.
    J Immunol; 1987 Apr 01; 138(7):2359-65. PubMed ID: 2951438
    [Abstract] [Full Text] [Related]

  • 6. Deficient tumor-specific immunity in old mice: in vivo mediation by suppressor cells, and correction of the defect by interleukin 2 supplementation in vitro but not in vivo.
    Bruley-Rosset M, Payelle B.
    Eur J Immunol; 1987 Mar 01; 17(3):307-12. PubMed ID: 2952510
    [Abstract] [Full Text] [Related]

  • 7. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study.
    Seledtsov VI, Taraban VY, Seledtsova GV, Samarin DM, Avdeev IV, Senyukov VV, Kozlov VA.
    Cell Immunol; 1997 Nov 25; 182(1):12-9. PubMed ID: 9427805
    [Abstract] [Full Text] [Related]

  • 8. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM, Kawashima K, Nakashima I, Nagase F.
    Cancer Res; 1988 Nov 15; 48(22):6450-4. PubMed ID: 3263189
    [Abstract] [Full Text] [Related]

  • 9. Pyran (MVE-5) reverses the inhibition of macrophage receptors for cytophilic antibody induced by soluble immune complexes.
    Rao VS, Mitchell MS.
    J Biol Response Mod; 1983 Nov 15; 2(1):67-80. PubMed ID: 6606020
    [Abstract] [Full Text] [Related]

  • 10. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
    Umezawa H, Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T.
    Cancer Res; 1987 Jun 15; 47(12):3062-5. PubMed ID: 3495325
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
    Lee FH, Currie D, Hwang KM.
    Cancer Res; 1984 Dec 15; 44(12 Pt 1):5491-8. PubMed ID: 6208997
    [Abstract] [Full Text] [Related]

  • 12. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T, Igarashi T, Kishimoto S.
    J Natl Cancer Inst; 1987 Mar 15; 78(3):509-17. PubMed ID: 2950265
    [Abstract] [Full Text] [Related]

  • 13. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
    Reichert CM, Rosenstein M, Von Glatz J, Hsu SM, Rosenberg SA.
    Lab Invest; 1985 Mar 15; 52(3):304-13. PubMed ID: 3974201
    [Abstract] [Full Text] [Related]

  • 14. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
    Kataoka T, Oh-hashi F, Sakurai Y, Gomi K.
    Cancer Res; 1980 Oct 15; 40(10):3832-8. PubMed ID: 6254642
    [Abstract] [Full Text] [Related]

  • 15. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.
    Elgert KD, Farrar WL.
    J Immunol; 1978 Apr 15; 120(4):1345-53. PubMed ID: 305939
    [Abstract] [Full Text] [Related]

  • 16. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
    Bernstein ID.
    J Immunol; 1977 Jan 15; 118(1):122-8. PubMed ID: 830744
    [Abstract] [Full Text] [Related]

  • 17. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
    Nagarkatti M, Toney DM, Nagarkatti PS.
    Cancer Res; 1989 Dec 01; 49(23):6587-92. PubMed ID: 2573418
    [Abstract] [Full Text] [Related]

  • 18. Immune mechanisms in leukemia: protective capacity of the major lymphoid cell compartments.
    Lukasewycz OA, Duffey PS, Murphy WH.
    J Immunol; 1976 Apr 01; 116(4):976-81. PubMed ID: 1082909
    [Abstract] [Full Text] [Related]

  • 19. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW, Mokyr MB.
    Cancer Res; 1984 Sep 01; 44(9):3873-9. PubMed ID: 6611201
    [Abstract] [Full Text] [Related]

  • 20. Immune response to murine neuroblastoma: effects of in vitro culture of the tumor. Mitogen and mixed lymphocyte culture responses, interleukin-2 production, suppression and natural killer activity.
    Leclercq G, Willems J, Joniau M.
    J Clin Lab Immunol; 1986 Nov 01; 21(3):117-23. PubMed ID: 2951523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.